This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grant, R.M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. published online, 10.1056/NEJMoa1011205 (23 November 2010).
Karim, Q.A. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–1174, 2010.
Donnell, D. et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375, 2092–2098 (2010).
Gallant, J.E., Parish, M.A., Keruly, J.C. & Moore, R.D. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 40, 1194–1198 (2005).
Golub, S.A., Kowalczyk, W., Weinberger, C.L. & Parsons, J.T. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J. Acquir. Immune Defic. Syndr. 54, 548–555 (2010).
Mellors, J.W. Closing in on HIV-1: antiretroviral therapy back on track with HIV-1 protease inhibitors. Nat. Med. 2, 1–2 (1996).
Cohen, M.S., Hellmann, N., Levy, J.A., DeCock, K. & Lange, J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J. Clin. Invest. 118, 1244–1154 (2008).
Cohen, M.S., Gay, C., Kashuba, A.D., Blower, S. & Paxton, L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146, 591–601 (2007).
Garcia-Lerma, J.G. et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infect. Science Transl. Med. 13, 14ra4 (2010).
Ethics declarations
Competing interests
S.G.D. has received research support from Gilead Sciences.
J.W.M. is a consultant to Gilead Sciences, Merck and RFS Pharma. He also holds share options in RFS Pharma, an early-stage biotech company that is developing new therapeutics for HIV and hepatitis C virus.
Rights and permissions
About this article
Cite this article
The ART of preventing HIV. Nat Med 17, 46–47 (2011). https://doi.org/10.1038/nm0111-46
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0111-46